Cargando...
Siltuximab (CNTO 328): a promising option for human malignancies
Siltuximab (CNTO 328) is a promising antibody-drug conjugate targeting cytokine interleukin-6 (IL-6). It is highly binding to IL-6 and thus neutralizing IL-6 bioactivity and promoting death of tumor cell. In this review, we mainly focus on the mechanisms, clinical studies, and adverse effect of silt...
Gardado en:
| Publicado en: | Drug Des Devel Ther |
|---|---|
| Main Authors: | , |
| Formato: | Artigo |
| Idioma: | Inglês |
| Publicado: |
Dove Medical Press
2015
|
| Assuntos: | |
| Acceso en liña: | https://ncbi.nlm.nih.gov/pmc/articles/PMC4494175/ https://ncbi.nlm.nih.gov/pubmed/26170629 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.2147/DDDT.S86438 |
| Tags: |
Engadir etiqueta
Sen Etiquetas, Sexa o primeiro en etiquetar este rexistro!
|